Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

被引：0
|
作者：
Sayegh, N. [1 ]
Jo, Y. Jung [1 ]
Gebrael, G. [1 ]
Tripathi, N. [1 ]
Chigarira, B. [1 ]
Srivastava, A. [1 ]
Nordblad, B. [1 ]
Dal, E. [1 ]
Chehade, C. Hage [1 ]
Maughan, B. L. [1 ]
Gupta, S. [1 ]
Agarwal, N. [1 ]
Swami, U. [1 ]
机构：
[1] Univ Utah Hlth, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2380P
引用
收藏
页码：S1212 / S1212
页数：1
相关论文
共 50 条
  • [31] Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
    Yao, W.
    Zhao, X.
    Gong, Y.
    Zhang, M.
    Zhang, L.
    Wu, Q.
    Wu, L.
    Fan, Z.
    Yan, X.
    Jiao, S.
    ESMO OPEN, 2021, 6 (02)
  • [32] The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis
    Kotecha, Rupesh
    Kim, Joseph M.
    Miller, Jacob A.
    Juloori, Aditya
    Chao, Samuel T.
    Murphy, Erin S.
    Peereboom, David M.
    Mohammadi, Alireza M.
    Barnett, Gene H.
    Vogelbaum, Michael A.
    Angelov, Lilyana
    Suh, John H.
    Ahluwalia, Manmeet S.
    NEURO-ONCOLOGY, 2019, 21 (08) : 1060 - 1068
  • [33] Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
    Li, Xiang
    Yan, Shi
    Yang, Jichun
    Wang, Yaqi
    Lv, Chao
    Li, Shaolei
    Zhao, Jun
    Yang, Yue
    Zhuo, Minglei
    Wu, Nan
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [34] PD-L1, PD-1 expression associated with clinicopathologic characteristics of patients with upper tract urothelial carcinoma
    Li, Pengchao
    Lu, Qiang
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 : 44 - 44
  • [35] Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
    Nan Zhang
    Xu Yang
    Mingjian Piao
    Ziyu Xun
    Yunchao Wang
    Cong Ning
    Xinmu Zhang
    Longhao Zhang
    Yanyu Wang
    Shanshan Wang
    Jiashuo Chao
    Zhenhui Lu
    Xiaobo Yang
    Hanping Wang
    Haitao Zhao
    Biomarker Research, 12
  • [36] Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
    Zhang, Nan
    Yang, Xu
    Piao, Mingjian
    Xun, Ziyu
    Wang, Yunchao
    Ning, Cong
    Zhang, Xinmu
    Zhang, Longhao
    Wang, Yanyu
    Wang, Shanshan
    Chao, Jiashuo
    Lu, Zhenhui
    Yang, Xiaobo
    Wang, Hanping
    Zhao, Haitao
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [37] Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action
    Xue, Yingyan
    Gao, Song
    Gou, Jingxin
    Yin, Tian
    He, Haibing
    Wang, Yanjiao
    Zhang, Yu
    Tang, Xing
    Wu, Rong
    EXPERT OPINION ON DRUG DELIVERY, 2021, 18 (02) : 187 - 203
  • [38] Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
    McGregor, Bradley
    O'Donnell, Peter H.
    Balar, Arjun
    Petrylak, Daniel
    Rosenberg, Jonathan
    Yu, Evan Y.
    Quinn, David, I
    Heath, Elisabeth, I
    Campbell, Mary
    Hepp, Zsolt
    McKay, Caroline
    Steinberg, Joyce
    Regnault, Antoine
    Mazerolle, Flora
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2022, 81 (05) : 515 - 522
  • [39] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [40] PD-1/PD-L1 blockade as first line systematic therapy in locally advanced cutaneous head and neck squamous cell carcinoma
    Ho, E.
    Hu, K. S.
    Liu, C. Z.
    DeLacure, M.
    Persky, M.
    Jacobson, A.
    Ratner, D.
    Li, Z.
    Givi, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1183 - 1183
12345